NCT07161700

AUG 17, 2026 · PHASE 2 TRIAL

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

ClinicalTrials.gov

This is a Phase 2 open-label extension study with no results posted; it is designed to assess safety and tolerability in a planned 360-participant cohort, typical of early-phase investigation.